Striatal dopamine D1 and D2 receptors: Widespread influences on methamphetamine-induced dopamine and serotonin neurotoxicity

Synapse

Volumn 65, Issue 11, 2011, Pages 1144-1155

  Gross, Noah B ^a   Duncker, Patrick C ^a   Marshall, John F ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Basal ganglia; Cerebral cortex; Dopamine transporter; Glutamate; Neuroprotection; Psychostimulant; Serotonin transporter

Indexed keywords

8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE TRANSPORTER; METHAMPHETAMINE; SEROTONIN TRANSPORTER; SULPIRIDE;

AMYGDALOID NUCLEUS; ANIMAL EXPERIMENT; ARTICLE; BODY TEMPERATURE; BRAIN CORTEX; CORPUS STRIATUM; FEVER; HIPPOCAMPUS; MALE; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR BINDING; RECEPTOR BLOCKING;

ANIMALS; CORPUS STRIATUM; DOPAMINE; DOPAMINE ANTAGONISTS; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; MALE; METHAMPHETAMINE; PROTEIN BINDING; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2; SEROTONIN; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS;

EID: 80052381726     PISSN: 08874476     EISSN: 10982396     Source Type: Journal    
DOI: 10.1002/syn.20952     Document Type: Article

References (42)

1. Albers DS, Sonsalla PK. 1995. Methamphetamine-induced hyperthermia and dopaminergic neurotoxicity in mice: Pharmacological profile of protective and nonprotective agents. J Pharmacol Exp Ther 275: 1104-1114.
2. Alexander GE, Crutcher MD. 1990. Functional architecture of basal ganglia circuits: Neural substrates of parallel processing. Trends Neurosci 13: 266-271.
3. Belcher AM, O'Dell SJ, Marshall JF. 2005. Impaired object recognition memory following methamphetamine, but not p-chloroamphetamine- or d-amphetamine-induced neurotoxicity. Neuropsychopharmacology 30: 2026-2034.
4. Broening HW, Morford LL, Vorhees CV. 2005. Interactions of dopamine D1 and D2 receptor antagonists with D-methamphetamine-induced hyperthermia and striatal dopamine and serotonin reductions. Synapse 56: 84-93.
5. Chang L, Alicata D, Ernst T, Volkow N. 2007. Structural and metabolic brain changes in the striatum associated with methamphetamine abuse. Addiction 102 (Suppl 1): 16-32.
6. Cheramy A, Romo R, Glowinski J. 1985. Dopamine release and neuronal activity in the two nigrostriatal systems. In: Bayon A, Drucker-Colin R, editors. In vivo perfusion and release of neuroactive substances. New York: Academic Press. p 161-175.
7. Eisch AJ, Gaffney M, Weihmuller FB, O'Dell SJ, Marshall JF. 1992. Striatal subregions are differentially vulnerable to the neurotoxic effects of methamphetamine. Brain Res 598 (1-2): 321-326.
8. Eisch AJ, Marshall JF. 1998. Methamphetamine neurotoxicity: Dissociation of striatal dopamine terminal damage from parietal cortical cell body injury. Synapse 30: 433-445.
9. Fleckenstein AE, Volz TJ, Riddle EL, Gibb JW, Hanson GR. 2007. New insights into the mechanism of action of amphetamines. Annu Rev Pharmacol Toxicol 47: 681-698.
10. Gerfen CR. 1992. The neostriatal mosaic: Multiple levels of compartmental organization. Trends Neurosci 15: 133-139.
11. Graybiel AM. 1990. Neurotransmitters and neuromodulators in the basal ganglia. Trends Neurosci 13: 244-254.
12. Gross NB, Marshall JF. 2009. Striatal dopamine and glutamate receptors modulate methamphetamine-induced cortical Fos expression. Neuroscience 161: 1114-1125.
13. Hotchkiss AJ, Morgan ME, Gibb JW. 1979. The long-term effects of multiple doses of methamphetamine on neostriatal tryptophan hydroxylase, tyrosine hydroxylase, choline acetyltransferase and glutamate decarboxylase activities. Life Sci 25: 1373-1378.
14. Huang YH, Tsai SJ, Su TW, Sim CB. 1999. Effects of repeated high-dose methamphetamine on local cerebral glucose utilization in rats. Neuropsychopharmacology 21: 427-434.
15. Joel D, Weiner I. 1994. The organization of the basal ganglia-thalamocortical circuits: Open interconnected rather than closed segregated. Neuroscience 63: 363-379.
16. Johanson CE, Frey KA, Lundahl LH, Keenan P, Lockhart N, Roll J, Galloway GP, Koeppe RA, Kilbourn MR, Robbins T, Schuster CR. 2006. Cognitive function and nigrostriatal markers in abstinent methamphetamine abusers. Psychopharmacology (Berl) 185: 327-338.
17. Kim SJ, Lyoo IK, Hwang J, Sung YH, Lee HY, Lee DS, Jeong DU, Renshaw PF. 2005. Frontal glucose hypometabolism in abstinent methamphetamine users. Neuropsychopharmacology 30: 1383-1391.
18. London ED, Simon SL, Berman SM, Mandelkern MA, Lichtman AM, Bramen J, Shinn AK, Miotto K, Learn J, Dong Y, Matochik JA, Kurian V, Newton T, Woods R, Rawson R, Ling W. 2004. Mood disturbances and regional cerebral metabolic abnormalities in recently abstinent methamphetamine abusers. Arch Gen Psychiatry 61: 73-84.
19. Mark KA, Quinton MS, Russek SJ, Yamamoto BK. 2007. Dynamic changes in vesicular glutamate transporter 1 function and expression related to methamphetamine-induced glutamate release. J Neurosci 27: 6823-6831.
20. Mark KA, Soghomonian JJ, Yamamoto BK. 2004. High-dose methamphetamine acutely activates the striatonigral pathway to increase striatal glutamate and mediate long-term dopamine toxicity. J Neurosci 24: 11449-11456.
21. Marshall JF, Henry BL, Billings LM, Hoover BR. 2001. The role of the globus pallidus D2 subfamily of dopamine receptors in pallidal immediate early gene expression. Neuroscience 105: 365-378.
22. McFarland NR, Haber SN. 2002. Thalamic relay nuclei of the basal ganglia form both reciprocal and nonreciprocal cortical connections, linking multiple frontal cortical areas. J Neurosci 22: 8117-8132.
23. McGeorge AJ, Faull RL. 1989. The organization of the projection from the cerebral cortex to the striatum in the rat. Neuroscience 29: 503-537.
24. Nash JF, Yamamoto BK. 1992. Methamphetamine neurotoxicity and striatal glutamate release: Comparison to 3, 4-methylenedioxymethamphetamine. Brain Res 581: 237-243.
25. Neisewander JL, O'Dell LE, Redmond JC. 1995. Localization of dopamine receptor subtypes occupied by intra-accumbens antagonists that reverse cocaine-induced locomotion. Brain Res 671: 201-212.
26. O'Dell SJ, Weihmuller FB, Marshall JF. 1993. Methamphetamine-induced dopamine overflow and injury to striatal dopamine terminals: Attenuation by dopamine D1 or D2 antagonists. J Neurochem 60: 1792-1799.
27. Paulus MP, Hozack N, Frank L, Brown GG, Schuckit MA. 2003. Decision making by methamphetamine-dependent subjects is associated with error-rate-independent decrease in prefrontal and parietal activation. Biol Psychiatry 53: 65-74.
28. Paxinos G, Watson C. 2003. The rat brain Atlas in stereotaxic coordinates. Sydney, Australia: Academic Press.
29. Pontieri FE, Crane AM, Seiden LS, Kleven MS, Porrino LJ. 1990. Metabolic mapping of the effects of intravenous methamphetamine administration in freely moving rats. Psychopharmacology (Berl) 102: 175-182.
30. Ricaurte GA, Guillery RW, Seiden LS, Schuster CR, Moore RY. 1982. Dopamine nerve terminal degeneration produced by high doses of methylamphetamine in the rat brain. Brain Res 235: 93-103.
31. Ricaurte GA, Schuster CR, Seiden LS. 1980. Long-term effects of repeated methylamphetamine administration on dopamine and serotonin neurons in the rat brain: A regional study. Brain Res 193: 153-163.
32. Rocher C, Gardier AM. 2001. Effects of repeated systemic administration of d-Fenfluramine on serotonin and glutamate release in rat ventral hippocampus: Comparison with methamphetamine using in vivo microdialysis. Naunyn Schmiedebergs Arch Pharmacol 363: 422-428.
33. Scott JC, Woods SP, Matt GE, Meyer RA, Heaton RK, Atkinson JH, Grant I. 2007. Neurocognitive effects of methamphetamine: A critical review and meta-analysis. Neuropsychol Rev 17: 275-297.
34. Seiden LS, Commins DL, Vosmer G, Axt K, Marek G. 1988. Neurotoxicity in dopamine and 5-hydroxytryptamine terminal fields: A regional analysis in nigrostriatal and mesolimbic projections. Ann N Y Acad Sci 537: 161-172.
35. Sekine Y, Ouchi Y, Takei N, Yoshikawa E, Nakamura K, Futatsubashi M, Okada H, Minabe Y, Suzuki K, Iwata Y, Tsuchiya KJ, Tsukada H, Iyo M, Mori N. 2006. Brain serotonin transporter density and aggression in abstinent methamphetamine abusers. Arch Gen Psychiatry 63: 90-100.
36. Sonsalla PK, Gibb JW, Hanson GR. 1986. Roles of D1 and D2 dopamine receptor subtypes in mediating the methamphetamine-induced changes in monoamine systems. J Pharmacol Exp Ther 238: 932-937.
37. Steiner H, Kitai ST. 2000. Regulation of rat cortex function by D1 dopamine receptors in the striatum. J Neurosci 20: 5449-5460.
38. Stephans SE, Yamamoto BK. 1994. Methamphetamine-induced neurotoxicity: Roles for glutamate and dopamine efflux. Synapse 17: 203-209.
39. Sulzer D, Sonders MS, Poulsen NW, Galli A. 2005. Mechanisms of neurotransmitter release by amphetamines: A review. Prog Neurobiol 75: 406-433.
40. Vertes RP. 2006. Interactions among the medial prefrontal cortex, hippocampus and midline thalamus in emotional and cognitive processing in the rat. Neuroscience 142: 1-20.
41. Volkow ND, Chang L, Wang GJ, Fowler JS, Leonido-Yee M, Franceschi D, Sedler MJ, Gatley SJ, Hitzemann R, Ding YS, Logan J, Wong C, Miller EN. 2001. Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. Am J Psychiatry 158: 377-382.
42. Yano M, Beverley JA, Steiner H. 2006. Inhibition of methylphenidate-induced gene expression in the striatum by local blockade of D1 dopamine receptors: Interhemispheric effects. Neuroscience 140: 699-709.